Brokerages Set Envista Holdings Corporation (NYSE:NVST) Price Target at $21.54

Envista Holdings Corporation (NYSE:NVST) has been given a consensus rating of “Hold” by the sixteen research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $21.7692.

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d)” rating on shares of Envista in a report on Monday. Stifel Nicolaus set a $25.00 price objective on Envista in a research report on Thursday, October 30th. Barclays started coverage on shares of Envista in a report on Monday, December 8th. They set an “overweight” rating and a $24.00 target price on the stock. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in Envista by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,375,109 shares of the company’s stock worth $40,994,000 after acquiring an additional 57,478 shares during the last quarter. Invesco Ltd. boosted its holdings in Envista by 2.9% during the first quarter. Invesco Ltd. now owns 353,089 shares of the company’s stock worth $6,094,000 after purchasing an additional 9,950 shares during the last quarter. Nuveen LLC bought a new position in Envista in the first quarter valued at $5,347,000. Fox Run Management L.L.C. bought a new position in Envista in the first quarter valued at $417,000. Finally, Dimensional Fund Advisors LP increased its stake in Envista by 24.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company’s stock valued at $144,760,000 after buying an additional 1,625,206 shares during the last quarter.

Envista Price Performance

Envista stock opened at $21.84 on Monday. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $3.59 billion, a P/E ratio of 242.64, a PEG ratio of 1.08 and a beta of 1.02. The business has a 50-day moving average of $20.25 and a 200-day moving average of $20.20. Envista has a 1 year low of $14.22 and a 1 year high of $22.68.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Envista had a net margin of 0.58% and a return on equity of 5.90%. The firm had revenue of $669.90 million during the quarter, compared to analysts’ expectations of $639.49 million. During the same quarter in the previous year, the company earned $0.12 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, equities analysts anticipate that Envista will post 1 EPS for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.